Acquisition Synergy Post-acquisition by Ginkgo Bioworks, Proof Diagnostics gains access to a broader enterprise customer base and complementary capabilities in gene editing. Opportunity to cross-sell the CRISPR-based diagnostics platform to Ginkgo's biotech and pharma clients and integrate with allied workflows.

Point-of-Care Targeting The platform is designed for clinics, pharmacies, schools, and workplaces, presenting near-term sales opportunities with institutions seeking rapid, high-quality SARS-CoV-2 testing and scalable deployment.

Regulatory Readiness ISO 13485 and related quality systems position Proof to meet healthcare procurement requirements, reducing sales cycles with regulated buyers and enabling faster onboarding.

Future Disease Portfolio Beyond SARS-CoV-2, the roadmap to expand into additional diseases offers ongoing demand generation opportunities with healthcare systems seeking an adaptable diagnostic platform.

Funding & Scale Strong funding and a clear R&D pipeline under a leading biotech group create opportunities to run pilots, establish reference customers, and scale through established medical device distribution channels.